Minerva Neurosciences (NERV) Competitors

$5.50 -0.05 (-0.90%)

Closing price 04:00 PM Eastern

Extended Trading

$5.50 0.00 (0.00%)

As of 05:51 PM Eastern

NERV vs. DBVT, SEPN, SVRA, XERS, and ALVO

Should you buy Minerva Neurosciences stock or one of its competitors? MarketBeat compares Minerva Neurosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Minerva Neurosciences include DBV Technologies (DBVT), Septerna (SEPN), Savara (SVRA), Xeris Biopharma (XERS), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry.

How does Minerva Neurosciences compare to DBV Technologies?

DBV Technologies (NASDAQ:DBVT) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

DBV Technologies currently has a consensus target price of $40.25, suggesting a potential upside of 102.87%. Minerva Neurosciences has a consensus target price of $10.50, suggesting a potential upside of 90.91%. Given DBV Technologies' stronger consensus rating and higher possible upside, research analysts plainly believe DBV Technologies is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.67
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

DBV Technologies is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	N/A	N/A	-$146.95M	-$4.46	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 1.4% of DBV Technologies shares are held by company insiders. Comparatively, 10.4% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Minerva Neurosciences has a net margin of 0.00% compared to DBV Technologies' net margin of -2,895.37%. Minerva Neurosciences' return on equity of 0.00% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-2,895.37%	-129.88%	-88.84%
Minerva Neurosciences	N/A	N/A	-32.63%

DBV Technologies has a beta of -0.96, meaning that its stock price is 196% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.08, meaning that its stock price is 108% less volatile than the broader market.

In the previous week, DBV Technologies had 2 more articles in the media than Minerva Neurosciences. MarketBeat recorded 4 mentions for DBV Technologies and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.68 beat DBV Technologies' score of 0.47 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Minerva Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

DBV Technologies beats Minerva Neurosciences on 8 of the 15 factors compared between the two stocks.

How does Minerva Neurosciences compare to Septerna?

Minerva Neurosciences (NASDAQ:NERV) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

Minerva Neurosciences has a beta of -0.08, indicating that its share price is 108% less volatile than the broader market. Comparatively, Septerna has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market.

Minerva Neurosciences presently has a consensus price target of $10.50, suggesting a potential upside of 90.91%. Septerna has a consensus price target of $43.13, suggesting a potential upside of 52.28%. Given Minerva Neurosciences' higher probable upside, equities research analysts clearly believe Minerva Neurosciences is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Septerna has higher revenue and earnings than Minerva Neurosciences. Septerna is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A
Septerna	$45.95M	27.78	-$48.88M	-$1.11	N/A

In the previous week, Septerna had 5 more articles in the media than Minerva Neurosciences. MarketBeat recorded 7 mentions for Septerna and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.68 beat Septerna's score of 0.48 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Septerna	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Minerva Neurosciences has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Minerva Neurosciences' return on equity of 0.00% beat Septerna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-32.63%
Septerna	-49.88%	-12.72%	-8.87%

34.6% of Minerva Neurosciences shares are held by institutional investors. 10.4% of Minerva Neurosciences shares are held by insiders. Comparatively, 4.3% of Septerna shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Septerna beats Minerva Neurosciences on 9 of the 16 factors compared between the two stocks.

How does Minerva Neurosciences compare to Savara?

Minerva Neurosciences (NASDAQ:NERV) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

Minerva Neurosciences presently has a consensus price target of $10.50, indicating a potential upside of 90.91%. Savara has a consensus price target of $9.13, indicating a potential upside of 73.15%. Given Minerva Neurosciences' higher probable upside, equities research analysts clearly believe Minerva Neurosciences is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Savara	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Minerva Neurosciences has a beta of -0.08, meaning that its share price is 108% less volatile than the broader market. Comparatively, Savara has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

Minerva Neurosciences' return on equity of 0.00% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-32.63%
Savara	N/A	-92.93%	-69.60%

In the previous week, Savara had 4 more articles in the media than Minerva Neurosciences. MarketBeat recorded 6 mentions for Savara and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.68 beat Savara's score of 0.60 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Savara is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 10.4% of Minerva Neurosciences shares are held by company insiders. Comparatively, 5.3% of Savara shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Savara beats Minerva Neurosciences on 8 of the 14 factors compared between the two stocks.

How does Minerva Neurosciences compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Xeris Biopharma has a net margin of 3.81% compared to Minerva Neurosciences' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Minerva Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Minerva Neurosciences	N/A	N/A	-32.63%

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are owned by institutional investors. 6.5% of Xeris Biopharma shares are owned by insiders. Comparatively, 10.4% of Minerva Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Xeris Biopharma currently has a consensus target price of $10.80, indicating a potential upside of 69.28%. Minerva Neurosciences has a consensus target price of $10.50, indicating a potential upside of 90.91%. Given Minerva Neurosciences' higher probable upside, analysts clearly believe Minerva Neurosciences is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Xeris Biopharma had 12 more articles in the media than Minerva Neurosciences. MarketBeat recorded 14 mentions for Xeris Biopharma and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.68 beat Xeris Biopharma's score of 0.58 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Minerva Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Xeris Biopharma has higher revenue and earnings than Minerva Neurosciences. Minerva Neurosciences is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$314.85M	3.50	$550K	$0.06	106.33
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A

Xeris Biopharma has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.08, suggesting that its share price is 108% less volatile than the broader market.

Summary

Xeris Biopharma beats Minerva Neurosciences on 12 of the 15 factors compared between the two stocks.

How does Minerva Neurosciences compare to Alvotech?

Alvotech (NASDAQ:ALVO) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Minerva Neurosciences has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Minerva Neurosciences' return on equity of 0.00% beat Alvotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-14.36%	-11.92%	-7.58%
Minerva Neurosciences	N/A	N/A	-32.63%

Alvotech has higher revenue and earnings than Minerva Neurosciences. Alvotech is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$588.90M	1.76	$27.92M	-$0.25	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A

In the previous week, Alvotech had 7 more articles in the media than Minerva Neurosciences. MarketBeat recorded 9 mentions for Alvotech and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.68 beat Alvotech's score of 0.27 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alvotech	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Minerva Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Alvotech currently has a consensus price target of $7.60, indicating a potential upside of 121.57%. Minerva Neurosciences has a consensus price target of $10.50, indicating a potential upside of 90.91%. Given Alvotech's higher probable upside, equities analysts clearly believe Alvotech is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

34.6% of Minerva Neurosciences shares are owned by institutional investors. 0.5% of Alvotech shares are owned by company insiders. Comparatively, 10.4% of Minerva Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Alvotech has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.08, meaning that its stock price is 108% less volatile than the broader market.

Summary

Alvotech beats Minerva Neurosciences on 8 of the 14 factors compared between the two stocks.

Get Minerva Neurosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NERV vs. The Competition

Export

Metric	Minerva Neurosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$256.25M	$3.04B	$6.29B	$12.46B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-0.19	19.11	20.89	25.59
Price / Sales	N/A	280.24	522.17	62.83
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	-1.01	4.35	9.86	6.70
Net Income	-$293.42M	$72.19M	$3.55B	$333.77M
7 Day Performance	-10.28%	-0.62%	-0.32%	0.45%
1 Month Performance	-6.30%	0.22%	1.33%	4.06%
1 Year Performance	257.51%	46.24%	41.10%	36.24%

Minerva Neurosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NERV Minerva Neurosciences	2.1367 of 5 stars	$5.50 -0.9%	$10.50 +90.9%	+240.5%	$256.25M	N/A	N/A	9
DBVT DBV Technologies	2.9271 of 5 stars	$19.49 +0.1%	$40.25 +106.5%	+78.3%	$1.09B	N/A	N/A	80
SEPN Septerna	3.4143 of 5 stars	$24.13 -2.8%	$43.13 +78.7%	+267.8%	$1.08B	$45.95M	N/A	N/A	News Coverage Earnings Report Upcoming Earnings Analyst Forecast
SVRA Savara	2.5288 of 5 stars	$5.25 -0.9%	$9.13 +73.8%	+77.4%	$1.08B	N/A	N/A	20	Earnings Report
XERS Xeris Biopharma	3.0163 of 5 stars	$6.23 -1.7%	$10.80 +73.4%	+31.2%	$1.08B	$291.85M	N/A	290	Earnings Report Analyst Downgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NERV) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Minerva Neurosciences (NERV) Competitors

NERV vs. DBVT, SEPN, SVRA, XERS, and ALVO

How does Minerva Neurosciences compare to DBV Technologies?

Summary

How does Minerva Neurosciences compare to Septerna?

Summary

How does Minerva Neurosciences compare to Savara?

Summary

How does Minerva Neurosciences compare to Xeris Biopharma?

Summary

How does Minerva Neurosciences compare to Alvotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV vs. The Competition

Minerva Neurosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Minerva Neurosciences (NERV) Competitors

NERV vs. DBVT, SEPN, SVRA, XERS, and ALVO

How does Minerva Neurosciences compare to DBV Technologies?

Do analysts rate DBVT or NERV?

Which has stronger earnings and valuation, DBVT or NERV?

Do institutionals & insiders believe in DBVT or NERV?

Is DBVT or NERV more profitable?

Which has more volatility and risk, DBVT or NERV?

Does the media prefer DBVT or NERV?

Summary

How does Minerva Neurosciences compare to Septerna?

Which has more volatility & risk, NERV or SEPN?

Do analysts rate NERV or SEPN?

Which has higher earnings & valuation, NERV or SEPN?

Does the media prefer NERV or SEPN?

Is NERV or SEPN more profitable?

Do institutionals and insiders have more ownership in NERV or SEPN?

Summary

How does Minerva Neurosciences compare to Savara?

Do analysts rate NERV or SVRA?

Which has more risk and volatility, NERV or SVRA?

Is NERV or SVRA more profitable?

Does the media refer more to NERV or SVRA?

Which has higher valuation and earnings, NERV or SVRA?

Do insiders and institutionals hold more shares of NERV or SVRA?

Summary

How does Minerva Neurosciences compare to Xeris Biopharma?

Is XERS or NERV more profitable?

Do institutionals and insiders hold more shares of XERS or NERV?

Do analysts rate XERS or NERV?

Does the media refer more to XERS or NERV?

Which has stronger valuation & earnings, XERS or NERV?

Which has more volatility and risk, XERS or NERV?

Summary

How does Minerva Neurosciences compare to Alvotech?

Is ALVO or NERV more profitable?

Which has preferable valuation and earnings, ALVO or NERV?

Does the media refer more to ALVO or NERV?

Do analysts rate ALVO or NERV?

Do insiders and institutionals believe in ALVO or NERV?

Which has more volatility & risk, ALVO or NERV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV vs. The Competition

Minerva Neurosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools